Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.56 |
| ▸ | CNR1 | P21554 | 10/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22043106 | 0.90 | CNR2 (0.66) | CNR2CNR1MAPTNPC1RAB9A | |
| SCHEMBL29193377 | 0.90 | CNR2 (0.66) | CNR2CNR1MAPTNPC1RAB9A | |
| SCHEMBL28585334 | 0.90 | CNR2 (0.66) | CNR2CNR1MAPTNPC1RAB9A | |
| SCHEMBL2028907 | 0.86 | CNR2 (0.56) | CNR2CNR1MAPTNPC1RAB9A | |
| SCHEMBL2078826 | 0.85 | CNR2 (0.50) | CNR2CNR1 | |
| SCHEMBL4581678 | 0.83 | CNR2 (0.49) | CNR2CNR1 | |
| SCHEMBL14390805 | 0.82 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL14419136 | 0.82 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL1451288 | 0.81 | CNR2 (0.53) | CNR2CNR1ALDH1A1 | |
| SCHEMBL12657334 | 0.81 | CNR2 (0.45) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951842-B1 | USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS | BASF SE (DE) | 2016-07-27 | — | — | EP | disclosed |
| US-8501046-B2 | Use of rylene derivatives as photosensitizers in solar cells | BASF SE (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20120283432-A1 | USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS | MAX-PLANCK-GESEL. ZUR FOERDERUNG DER WISSEN. E.V. (DE) | 2012-11-08 | — | — | US | disclosed |
| US-8231809-B2 | Solid p-semiconductors may also be used in the inventive dye-sensitized solar cells without increasing the cell resistance, since the rylene derivatives absorb strongly and therefore require only thin n-semiconductor layers | BASF AKTIENGESELLSCHAFT (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20080269482-A1 | Use of Rylene Derivatives as Photosensitizers in Solar Cells | BASF SE (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1951842-A1 | USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS | BASF SE (DE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007054470-A1 | USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS | BASF SE (DE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283432-A1 | USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS | NR2E3, NR2E1, NR1D2 | CNR2 101/4885CNR1 188/4885MAPT 4643/4885 |
| US-20080269482-A1 | Use of Rylene Derivatives as Photosensitizers in Solar Cells | NR2E3, NR2E1, NR1D2 | CNR2 95/4885CNR1 163/4885MAPT 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.